Enovis Co. (NYSE:ENOV) Shares Sold by Price T Rowe Associates Inc. MD

Price T Rowe Associates Inc. MD trimmed its holdings in shares of Enovis Co. (NYSE:ENOV - Free Report) by 84.7% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 38,750 shares of the company's stock after selling 214,003 shares during the period. Price T Rowe Associates Inc. MD owned about 0.07% of Enovis worth $1,701,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors have also modified their holdings of ENOV. UMB Bank n.a. lifted its stake in Enovis by 128.2% during the 4th quarter. UMB Bank n.a. now owns 778 shares of the company's stock valued at $34,000 after acquiring an additional 437 shares during the period. Envestnet Portfolio Solutions Inc. lifted its stake in Enovis by 19.5% during the 4th quarter. Envestnet Portfolio Solutions Inc. now owns 15,433 shares of the company's stock valued at $677,000 after acquiring an additional 2,518 shares during the period. Assenagon Asset Management S.A. acquired a new stake in Enovis during the 4th quarter valued at approximately $437,000. Tributary Capital Management LLC increased its holdings in shares of Enovis by 33.9% during the 4th quarter. Tributary Capital Management LLC now owns 566,089 shares of the company's stock valued at $24,840,000 after purchasing an additional 143,258 shares in the last quarter. Finally, Park Avenue Securities LLC increased its holdings in shares of Enovis by 12.5% during the 4th quarter. Park Avenue Securities LLC now owns 11,988 shares of the company's stock valued at $526,000 after purchasing an additional 1,333 shares in the last quarter. 98.45% of the stock is currently owned by institutional investors.

Enovis Stock Down 2.7%

Shares of NYSE ENOV traded down $1.00 during midday trading on Wednesday, hitting $36.36. The company's stock had a trading volume of 269,538 shares, compared to its average volume of 774,131. The business's fifty day simple moving average is $35.18 and its two-hundred day simple moving average is $41.55. The company has a debt-to-equity ratio of 0.40, a current ratio of 2.27 and a quick ratio of 1.12. Enovis Co. has a 1 year low of $29.32 and a 1 year high of $53.84. The firm has a market capitalization of $2.08 billion, a price-to-earnings ratio of -16.60 and a beta of 1.79.

Enovis (NYSE:ENOV - Get Free Report) last posted its quarterly earnings data on Thursday, May 8th. The company reported $0.81 EPS for the quarter, beating the consensus estimate of $0.74 by $0.07. The business had revenue of $558.83 million during the quarter, compared to analyst estimates of $558.80 million. Enovis had a negative net margin of 5.95% and a positive return on equity of 4.39%. The business's revenue for the quarter was up 8.2% compared to the same quarter last year. During the same quarter last year, the firm posted $0.50 earnings per share. On average, equities analysts predict that Enovis Co. will post 2.79 EPS for the current year.

Wall Street Analysts Forecast Growth

Several brokerages have commented on ENOV. Canaccord Genuity Group dropped their price objective on Enovis from $75.00 to $70.00 and set a "buy" rating on the stock in a report on Wednesday. JMP Securities dropped their price objective on shares of Enovis from $62.00 to $55.00 and set a "market outperform" rating for the company in a report on Friday, May 9th. Finally, Needham & Company LLC dropped their price objective on shares of Enovis from $64.00 to $57.00 and set a "buy" rating for the company in a report on Friday, May 9th. One research analyst has rated the stock with a hold rating and four have assigned a buy rating to the company. According to data from MarketBeat.com, Enovis has an average rating of "Moderate Buy" and an average price target of $58.00.

About Enovis

Enovis Corporation operates as a medical technology company focus on developing clinically differentiated solutions worldwide. It also manufactures and distributes medical devices which are used for reconstructive surgery, rehabilitation, pain management, and physical therapy. The company operates through Prevention and Recovery, and Reconstructive segments.